Nottingham-founded Excellerate Biosciences has been bought by Oxford's spinout OMass Therapeutics, which unveiled a series A extension last week.
Excellerate Biosciences, a UK-based pharmacological services company spun out of University of Nottingham, has been acquired by drug developer OMass Therapeutics for an undisclosed sum.
Excellerate Bioscience supplies drug discovery services, including identifying targets and leads, to the pharmaceutical, biotechnology and research industries. The services are billed as employing state-of-the-art pharmacological technology.
OMass Therapeutics is a University of Oxford spinout, founded in 2016 to commercialise therapies for immunological and genetic disorders.
The company, which increased its series A round to $53.9m last week, believes Excellerate will bolster its capabilities in membrane protein pharmacology, a core component of its therapeutic approach.
Steven Charlton, co-founder and chief scientific officer of Excellerate, and professor of molecular pharmacology and drug discovery at University of Nottingham, has joined the OMass Therapeutics executive leadership.
Excellerate does not appear to have disclosed details of equity funding.
Ros Deegan, chief executive officer of OMass Therapeutics, said: “The acquisition of pharmacology capabilities from Excellerate is a key step in our journey towards an integrated company that discovers, develops and ultimately commercialises life-changing medicines for patients with immunological and genetic diseases.”
